BeStock  
Markets › Compare › ADMA vs RXRX

ADMA vs RXRX

Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.

vsvs
ADMA · ADMA Biologics$10.11 ▲ 4.01%
RXRX · Recursion Pharmaceuticals$4.78 ▲ 16.02%

One year, rebased to 100

Each line starts at 100 so growth is directly comparable

4974100126151Oct 7, '25Apr 7, '26Oct 5, '26
  • ADMA -27.7%
  • RXRX -8.6%

Head to head

MetricADMARXRX
Price$10.11$4.78
Change today▲ 4.01%▲ 16.02%
Market cap$2.26B$2.56B
Return, 3 months+9.8%+24.5%
Return, year to date-44.6%+16.9%
Return, 1 year-28.1%-13.6%
P/E (TTM)14.4-4.8
P/B5.52.8
P/E percentile vs own 5y–49th
Dividend yield––
Revenue growth (YoY, latest qtr)––
Net profit growth (YoY)––
Gross margin––
Operating margin––
Net margin––
Return on equity––
Analyst target vs. price+55.0%+39.1%
Analyst buy share67%40%
RSI (14)5972
30-day volatility41.2%89.6%
Max drawdown, 1 year-62.7%-58.2%
Trend readLeaning bullishStrong uptrend
Analyst consensusBuyBuy

Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.

What the numbers say

  • RXRX is the largest of the group by market value.
  • RXRX has returned the most over the past year.
  • RXRX carries the lowest trailing P/E.
  • ADMA has been the calmest stock over the last 30 days.

Go deeper

Scroll to Top